185 related articles for article (PubMed ID: 8285014)
1. A case of multiple myeloma with nuclear hypersegmentation after MP/VAD/VCAP-IFN therapies with a good prognosis.
Nara M; Suzuki K; Inoue Y; Enomoto H; Saito T; Fujioka S
Acta Haematol; 1993; 90(2):102-3. PubMed ID: 8285014
[No Abstract] [Full Text] [Related]
2. Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.
Zervas K; Pouli A; Gregoraki B; Anagnostopoulos N; Dimopoulos MA; Bourantas K; Tzilianos M; Barbarousi D; Venetis E; Vyniou N; Maniatis A
Eur J Haematol; 2001 Jan; 66(1):18-23. PubMed ID: 11168503
[TBL] [Abstract][Full Text] [Related]
3. Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol.
Pileri A; Barbui T; Boccadoro M; Comotti B; Dammacco F; Gallamini A; Marmont F; Neretto G; Petrucci MT; Resegotti L
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():168-9. PubMed ID: 2713554
[No Abstract] [Full Text] [Related]
4. Treatment strategies for plasma cell myeloma.
Smith L; Alexanian R
CA Cancer J Clin; 1985; 35(4):214-20. PubMed ID: 3926257
[No Abstract] [Full Text] [Related]
5. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
[TBL] [Abstract][Full Text] [Related]
6. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.
Peest D; Deicher H; Coldewey R; von Broen IM; Cammerer U; Hein R; Hoffmann L; Konyar H; Kreuser ED; Selbach J
Onkologie; 1990 Feb; 13(1):43-4. PubMed ID: 2186324
[TBL] [Abstract][Full Text] [Related]
7. [Recent therapy for refractory myeloma].
Togawa A
Rinsho Ketsueki; 1993 Apr; 34(4):450-4. PubMed ID: 8510332
[TBL] [Abstract][Full Text] [Related]
8. Nonsecretory multiple myeloma.
Bourantas K
Eur J Haematol; 1996; 56(1-2):109-11. PubMed ID: 8599984
[No Abstract] [Full Text] [Related]
9. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment Group.
Peest D; Deicher H; Coldewey R; Leo R; Bartl R; Bartels H; Braun HJ; von Broen IM; Fischer JT; Gramatzki M
Onkologie; 1990 Dec; 13(6):458-60. PubMed ID: 2092283
[TBL] [Abstract][Full Text] [Related]
10. [Progress in the treatment of multiple myeloma].
Wada M; Mizoguchi H
Gan To Kagaku Ryoho; 1997 Jul; 24(9):1079-88. PubMed ID: 9239160
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma.
Dimopoulos MA; Weber D; Delasalle KB; Alexanian R
Cancer; 1993 Nov; 72(9):2589-92. PubMed ID: 8402480
[TBL] [Abstract][Full Text] [Related]
12. Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group.
Zervas K; Pouli A; Perifanis V; Papanastasiou K; Chatziyianni M; Mitsouli C; Maniatis A
Eur J Haematol; 1996 Aug; 57(2):142-8. PubMed ID: 8856091
[TBL] [Abstract][Full Text] [Related]
13. [Recent progress in the treatment of hematological malignancies. V. Therapy of multiple myeloma].
Imamura Y
Nihon Naika Gakkai Zasshi; 1989 Jun; 78(6):809-13. PubMed ID: 2677178
[No Abstract] [Full Text] [Related]
14. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
[TBL] [Abstract][Full Text] [Related]
15. Multiple myeloma of the serosa coat.
Görg C; Adler G; Görg K; Pflüger KH; Havemann K
J Cancer Res Clin Oncol; 1988; 114(3):312-6. PubMed ID: 3384845
[TBL] [Abstract][Full Text] [Related]
16. IgE plasma cell leukemia successfully treated with combination VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon-alpha.
Yamagata N; Shimazaki C; Goto H; Hirata T; Ashihara E; Oku N; Inaba T; Fujita N; Nakagawa M
Am J Hematol; 1994 Mar; 45(3):262-4. PubMed ID: 8296801
[TBL] [Abstract][Full Text] [Related]
17. [Erythropoietin in multiple myeloma].
Pecherstorfer M; Schmoranzer F; Vesely M; Fortelny A; Baumgartner G
Dtsch Med Wochenschr; 1990 Jul; 115(28-29):1096-9. PubMed ID: 2373040
[TBL] [Abstract][Full Text] [Related]
18. The maturation of myeloma cells correlates with sensitivity to chemotherapeutic agents.
Kuroda Y; Sakai A; Okikawa Y; Munemasa S; Katayama Y; Hyodo H; Imagawa J; Takimoto Y; Okita H; Ohtaki M; Kimura A
Int J Hematol; 2005 May; 81(4):335-41. PubMed ID: 15914366
[TBL] [Abstract][Full Text] [Related]
19. VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85).
Mineur P; Ménard JF; Le Loët X; Bernard JF; Grosbois B; Pollet JP; Azais I; Laporte JP; Doyen C; De Gramont A; Wetterwald M; Euller-Ziegler L; Peny AM; Monconduit M; Michaux JL
Br J Haematol; 1998 Nov; 103(2):512-7. PubMed ID: 9827927
[TBL] [Abstract][Full Text] [Related]
20. High early mortality rate in elderly patients with multiple myeloma receiving a vincristine-doxorubicin-dexamethasone regimen.
Teng HW; Teng CJ; Wang WS; Chen PM; Chiou TJ; Hsu HC; Liu JH; Yen CC; Hsiao LT; Yang MH; Chao TC; Yang YH; Gau JP
Am J Hematol; 2010 Oct; 85(10):812-5. PubMed ID: 20734459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
